Lilly, MiNA Therapeutics partner to develop new drug candidates
The companies will leverage MiNA Therapeutics’ small activating RNA (saRNA) technology platform to develop the drug candidates. Using its saRNA platform, MiNA Therapeutics will research up to five
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.